StageZero Life Sciences Appoints Matthew J. Pietras as CFO and COO - Seite 2
Pietras brings two decades of financial executive experience, primarily at life science companies. Prior to joining StageZero Life Sciences, he was Vice President of Finance at Maryland-based CiVi Biopharma, where he was responsible for the oversight of Finance and Operations. Prior to that, he was Corporate Treasurer and Controller of Viela Bio from 2017 through 2019. At Viela Bio, the spin-out of AstraZeneca's AutoImmune Franchise, he was responsible for the design and implementation of the financial operations and preparing the company for its eventual IPO. From 2013 through 2017, he held senior finance roles at AstraZeneca/Medimmune, culminating in his position as Global Therapeutic Area Finance Director for the company's Oncology portfolio. He also held finance roles at Wells Fargo, Wachovia, and KPMG. He holds a B.S. in accounting and a B.S. in international business from Pennsylvania State University, and an M.S. in biotechnology and an MBA from Johns Hopkins University. Pietras is also a Certified Public Accountant.
About StageZero Life Sciences, Ltd.
StageZero Life Sciences is dedicated to the early detection of multiple diseases through whole blood tests. The Company's next-generation test, Aristotle®, is the first-ever multi-cancer panel for simultaneously screening for 10 cancers from a single sample of blood with high sensitivity and specificity for each cancer. StageZero's full service, telehealth platform includes access to physicians and phlebotomists who can prescribe and draw samples for individuals and groups, and the Company operates a CAP accredited and CLIA certified high-complexity reference laboratory in Richmond, Virginia. In addition, leveraging its specialty in polymerase chain reaction (PCR) testing for the early identification of cancer through blood, StageZero also provides both COVID PCR testing (swab and saliva) and blood test analysis (Antibody testing). For more information, please visit www.stagezerolifesciences.com.
Forward-Looking Statements
This press release contains forward-looking statements identified by words such as "expects", "will" and similar expressions, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties that could cause the Company's actual events to differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements, except as required by law.
For further information please contact:
Rebecca Greco
Investor Relations
Tel: 1-855-420-7140 ext. 1838
rgreco@stagezerols.com
Lesen Sie auch
SOURCE: StageZero Life Sciences Ltd
View source version on accesswire.com:
https://www.accesswire.com/658131/StageZero-Life-Sciences-Appoints-Mat ...